OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost Purchases 500,000 Shares

OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost acquired 500,000 shares of the company’s stock in a transaction dated Wednesday, December 11th. The shares were bought at an average price of $1.56 per share, for a total transaction of $780,000.00. Following the acquisition, the chief executive officer now directly owns 212,411,477 shares of the company’s stock, valued at approximately $331,361,904.12. This trade represents a 0.24 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is accessible through this link.

Phillip Md Et Al Frost also recently made the following trade(s):

• On Friday, December 13th, Phillip Md Et Al Frost bought 125,000 shares of OPKO Health stock. The stock was purchased at an average cost of $1.59 per share, with a total value of $198,750.00.
• On Friday, November 29th, Phillip Md Et Al Frost acquired 199,072 shares of OPKO Health stock. The stock was purchased at an average cost of $1.53 per share, with a total value of $304,580.16.
• On Friday, November 22nd, Phillip Md Et Al Frost bought 100,000 shares of OPKO Health stock. The shares were purchased at an average cost of $1.59 per share, for a total transaction of $159,000.00.
• On Thursday, November 14th, Phillip Md Et Al Frost purchased 100,000 shares of OPKO Health stock. The stock was acquired at an average cost of $1.62 per share, with a total value of $162,000.00.
• On Friday, November 8th, Phillip Md Et Al Frost acquired 280,183 shares of OPKO Health stock. The shares were acquired at an average price of $1.50 per share, for a total transaction of $420,274.50.

OPKO Health Stock Performance

NASDAQ OPK opened at $1.59 on Friday. The company has a fifty day moving average price of $1.53 and a 200-day moving average price of $1.47. The firm has a market cap of $1.09 billion, a price-to-earnings ratio of -8.37 and a beta of 1.62. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.97 and a quick ratio of 2.69. OPKO Health, Inc. has a 1 year low of $0.85 and a 1 year high of $1.76.

Analysts Set New Price Targets

Several research firms have recently commented on OPK. Barrington Research reissued an “outperform” rating and set a $2.25 target price on shares of OPKO Health in a research report on Friday, November 8th. HC Wainwright reissued a “buy” rating and set a $3.00 price objective on shares of OPKO Health in a report on Thursday, September 26th. Finally, Piper Sandler reissued an “overweight” rating and issued a $3.00 price objective on shares of OPKO Health in a research note on Tuesday, September 17th.

Institutional Investors Weigh In On OPKO Health

Institutional investors have recently added to or reduced their stakes in the company. CIBC Asset Management Inc lifted its position in shares of OPKO Health by 79.1% during the 2nd quarter. CIBC Asset Management Inc now owns 20,322 shares of the biotechnology company’s stock worth $25,000 after buying an additional 8,978 shares in the last quarter. Hollencrest Capital Management increased its position in shares of OPKO Health by 14.0% during the second quarter. Hollencrest Capital Management now owns 90,000 shares of the biotechnology company’s stock valued at $112,000 after acquiring an additional 11,020 shares during the last quarter. FMR LLC lifted its holdings in OPKO Health by 103.6% during the third quarter. FMR LLC now owns 21,795 shares of the biotechnology company’s stock worth $32,000 after acquiring an additional 11,089 shares during the period. Price T Rowe Associates Inc. MD lifted its holdings in OPKO Health by 4.1% during the first quarter. Price T Rowe Associates Inc. MD now owns 445,981 shares of the biotechnology company’s stock worth $536,000 after acquiring an additional 17,671 shares during the period. Finally, PFG Investments LLC boosted its position in OPKO Health by 2.5% in the second quarter. PFG Investments LLC now owns 960,965 shares of the biotechnology company’s stock worth $1,201,000 after purchasing an additional 23,700 shares during the last quarter. 64.63% of the stock is owned by institutional investors.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.